Bifemelane (hydrochloride)

Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a Ki of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a Ki of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease[1][2].

Product Specifications

CAS Number

[62232-46-6]

Product Name Alternative

MCI-2016

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/bifemelane-hydrochloride.html

Purity

99.86

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

CNCCCCOC1=CC=CC=C1CC2=CC=CC=C2.[H]Cl

Molecular Formula

C18H24ClNO

Molecular Weight

305.84

Precautions

H302, H315, H319, H335

References & Citations

[1]Naoi M, et, al. 4- (O-benzylphenoxy) -N-methylbutylamine (bifemelane) and other 4- (O-benzylphenoxy) -N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J Neurochem. 1988 Jan; 50 (1) : 243-7.|[2]Fasipe OJ, et, al. The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents. IBRO Rep. 2019 Jan 9; 6:95-110.|[3]Moryl E, et, al. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol. 1993 Jun; 72 (6) : 394-7.